VIVEVE MED INC
VIVE
VIVE was delisted on the 18th of January, 2023.
46 hedge funds and large institutions have $49.6M invested in VIVEVE MED INC in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 18 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 50 → 46 (-4)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
35% less capital invested
Capital invested by funds: $76.9M → $49.6M (-$27.3M)
59% less call options, than puts
Call options by funds: $18K | Put options by funds: $44K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.17M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.24M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$1.15M |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$893K |
| 5 |
RI
RTW Investments
New York
|
+$873K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$5.61M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.67M |
| 3 |
IG
ING Group
Amsterdam,
Netherlands
|
-$1.58M |
| 4 |
PA
Perceptive Advisors
New York
|
-$1.23M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.2M |
VIVE Hedge Fund Activity: Q2 2018 in Review
46 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in VIVEVE MED INC (VIVE) for Q2 2018, worth a combined $49.6M — down 35% from $76.9M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of VIVE and 14 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 14 added.
The largest buyer was Nantahala Capital Management, adding an estimated $3.17M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $5.61M sold.
- 46 institutional investors held VIVEVE MED INC (VIVE) as of Q2 2018, down from 50 in Q1 2018.
- Funds reported $49.6M of VIVEVE MED INC stock for Q2 2018, down 35% quarter-over-quarter.
- 14 funds opened new VIVEVE MED INC positions in Q2 2018 and 18 closed out, a net change of -4 holders.
- The largest VIVEVE MED INC buyer in Q2 2018 was Nantahala Capital Management, an estimated $3.17M added.
- The largest VIVEVE MED INC seller in Q2 2018 was Avoro Capital Advisors, an estimated $5.61M sold.
Based on aggregated 13F filings for Q2 2018.